CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 19 enrolled
Drug / intervention
Magnetic Levator Prosthesis (MLP)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03818204
NCT03818204N/ACompleted
CompareCT.gov

Clinical Trial to Improve the Magnetic Levator Prosthesis (MLP) Including the Development and Testing of a Novel Adjustable Force System

Massachusetts Eye and Ear Infirmary·interventional·Posted Jan 28, 2019·Updated Jun 13, 2025

In Brief

A clinical study evaluating Magnetic Levator Prosthesis (MLP) for Blepharoptosis and 4 related conditions. Completed, enrolled 19 participants across 1 site.

Detailed Summary

Blepharoptosis (incomplete opening of the eyelids) occurs because of a disruption in the normal agonist-antagonist neuro-muscular complex balance. An external device could restore eyelid movement. A newer class of permanent magnets made of alloys of neodymium (Nd), iron (Fe) and boron (B) might provide the technology needed to develop a feasible external magnetic device that could restore eyelid movement.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBlepharoptosis, Ptosis, Eyelid, Myasthenia Gravis, Stroke, Traumatic Brain Injury
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedJan 28, 2019
Enrollment StartFeb 7, 2019
Primary CompletionDec 1, 2023
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 7.4 years ago

Interventions

Magnetic Levator Prosthesis (MLP)device

Neodymium magnet embedded in a glasses frame and a polymer embedded (PDMS) micro-magnet array fitted externally to the upper lid with IV 3000 securement film. The IV 3000 is FDA approved for extended wear on the skin. Tegaderm, which is essentially the same adhesive, is even FDA approved as an eye covering (we used Tegaderm in early studies but switched to IV 3000 for its superior ease of handling based on packaging technique).